Am J Clin Pathol

1. CHAKRABORTY SR, Bickford MA, Smuliac NA, Tonseth KA, et al
   IGL::CCND1 detected by optical genome mapping revises diagnosis of a B-cell lymphoma.
   Am J Clin Pathol. 2025 Sep 10:aqaf096. doi: 10.1093.
   

   >> Share

   
   

   
   Am J Hematol

2. LIU Y, Ren Y, Gao L, Ahmed S, et al
   Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma Group.
   Am J Hematol. 2025 Sep 8. doi: 10.1002/ajh.70063.
   

   >> Share

   
   

   
   Blood

3. ZUCCA E, Ceriani L, Ciccone G, Di Rocco A, et al
   Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
   Blood. 2025 Sep 12:blood.2025028823. doi: 10.1182/blood.2025028823.
   

   >> Share

   
   
4. 
   Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025;145(20):2303-2311.
   Blood. 2025;146:1374.
   

   >> Share

   
   
5. FALCHI L, Sureda A, Leppa S, Vermaat JS, et al
   Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.
   Blood. 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909.
   

   >> Share

   
   

   
   Br J Haematol

6. KUHNL A, Bouziana S, Barrington SF, Galani S, et al
   MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.
   Br J Haematol. 2025 Sep 11. doi: 10.1111/bjh.70137.
   

   >> Share

   
   
7. VODICKA P, Hamova I, Velasova A, Kupcova K, et al
   Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.
   Br J Haematol. 2025 Sep 7. doi: 10.1111/bjh.70128.
   

   >> Share

   
   

   
   Cancer

8. TAN S, He H, Ni J, Guo Y, et al
   Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary ce
   Cancer. 2025;131:e70083.
   

   >> Share

   
   

   
   Hum Pathol

9. MEDEIROS LJ, Zhou J, Wang X, Wang W, et al
   Leukemic Phase of MYC/BCL2 Double-Hit High-grade B-cell Lymphoma: A report of 35 cases.
   Hum Pathol. 2025 Sep 7:105933. doi: 10.1016/j.humpath.2025.105933.
   

   >> Share

   
   

   
   PLoS One

10. VAUGHAN J, Patel M, Lawrie D, Machaba M, et al
    Correction: The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma.
    PLoS One. 2025;20:e0331945.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share